Salsalate
- Generic Name
- Salsalate
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10O5
- CAS Number
- 552-94-3
- Unique Ingredient Identifier
- V9MO595C9I
- Background
Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
- Indication
For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.
Role of Inflammation in Vascular Phenotype Associated with E-cigarette Use
- Conditions
- Endothelial DysfunctionInflammationElectronic Cigarette Use
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 24
- Registration Number
- NCT06489249
- Locations
- 🇺🇸
Iowa Bioscience Innovation Facility, Iowa City, Iowa, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy
- Conditions
- Diabetic Neuropathies
- Interventions
- Drug: Fish Oil Concentrate, 1000 Mg Oral Capsule
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 100
- Registration Number
- NCT05169060
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Endometriosis and Microvascular Dysfunction: Role of Inflammation
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 24
- Registration Number
- NCT05069740
- Locations
- 🇺🇸
The Pennsylvania State University, University Park, Pennsylvania, United States
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyeloblasts 10 Percent or More of Bone Marrow Nucleated CellsMyelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 5
- Registration Number
- NCT04146038
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control
- Conditions
- HyperglycemiaPerioperative/Postoperative ComplicationsDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- McMaster University
- Registration Number
- NCT03816488
Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
- Conditions
- Preeclampsia
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 32
- Registration Number
- NCT03482440
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Pennsylvania State University, University Park, Pennsylvania, United States
Salsalate in Patients Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Adam Boxer
- Target Recruit Count
- 40
- Registration Number
- NCT03277573
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03229408
- Locations
- 🇺🇸
Frank González, Chicago, Illinois, United States
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease
- Conditions
- Non Alcoholic Fatty LiverOsteo Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Korea University Guro Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03222206
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
- Conditions
- Peripheral NeuropathyType 1 Diabetes
- Interventions
- Drug: PLACEBO
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 61
- Registration Number
- NCT02936843
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Veterans Administration Ann Arbor Health Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.